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Background: Marine polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
have been associated with improvement in the Metabolic Syndrome (MS). The aim of this study is to evaluate how
three fish-oil diets with different eicosapentaenoic acid/docosahexaenoic acid ratios (EPA/DHA ratio) affect the
histology of liver, kidney, adipose tissue and aorta in a preliminary morphological study. This work uses an animal
model of metabolic syndrome in comparison with healthy animals in order to provide information about the best
EPA:DHA ratio to prevent or to improve metabolic syndrome symptoms.
Methods: 35 Wistar rats, as a control, and 35 spontaneously hypertensive obese rats (SHROB) were fed for 13 weeks
with 3 different suplemmentation of fish oil containing EPA and DHA ratios (1:1, 2:1 and 1:2, respectively). All
samples were stained with haematoxylin/eosin stain, except aorta samples, which were stained also with Verhoeff
and van Gieson’s stain. A histological study was carried out to evaluate changes. These changes were statistically
analyzed using SPSS IBM 19 software. The quantitative data were expressed by mean ± SD and were compared
among groups and treatments using ANOVA with post-hoc tests for parametric data and the U-Mann–Whitney for
non-parametric data. Qualitative data were expressed in frequencies, and compared with contingency tables using
χ2 statistics.
Results: EPA:DHA 1:1 treatment tended to improve the density and the wrinkling of elastic layers in SHROB rats.
Only Wistar rats fed with EPA:DHA 1:1 treatment did not show mast cells in adipose tissue and has less kidney
atrophy. In both strains EPA:DHA 1:1 treatment improved inflammation related parameters in liver and kidney.
Conclusions: EPA:DHA 1:1 treatment was the most beneficial treatment since improved many histological
parameters in both groups of rats.
Keywords: Metabolic syndrome, Omega-3-polyunsaturated fatty acids, EPA/DHA ratio, Histology, SHROB rats, Fish oilsBackground
Fish oils are the most common source of Omega-3 fatty
acids, mainly eicosapentaenoic acid, (EPA 20:5) and doco-
sahexaenoic acid, (DHA 22:6). It has been pointed out
protective effect and beneficial effects of these fatty acids
on heart health, cardiovascular disease (CVD), blood lipid
profile, Type 2 Diabetes mellitus (T2DM), inflammatory
and renal diseases and other illnesses [1,2]. Other potential* Correspondence: nuria.taltavull@urv.cat
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unless otherwise stated.mechanisms of cardiovascular protection by EPA/DHA
may include lowering blood pressure, reduced anti-
inflammatory effects, improved insulin resistance and
decrease oxidative stress [3,4].
Most of these signs and illnesses are related to meta-
bolic syndrome (MS). MS is defined as the presence of
at least three of the five cardiovascular disease risk fac-
tors in the following list: elevated fasting triglycerides
(TG), decreased high-density lipoprotein cholesterol, in-
sulin resistance, abdominal obesity and high blood pres-
sure [3,5]. Accordingly nutritional modifications such as
fish oil supplementation may correct MS.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and histological changes too, but little research has been
done on this issue [6].
Additionally, the amount of n-3 PUFA that needs to
be in the diet to provide healthy effects is still unknown
[7]. All fish contain EPA and DHA in amounts that vary
depending on species. The EPA/DHA ratio in fish ranges
between 0.22 and 1.25. The majority of the clinical stud-
ies carried-out to date use fish-oil derived dietary sup-
plements, but with a higher EPA/DHA ratio than that
commonly found in the fish themselves. There is some
controversy about the amounts of DHA or EPA that can
have a positive effect on the prevention of metabolic al-
terations and cardiovascular disease (CVD) [8].
Therefore, the aim of this study is to evaluate how
three fish-oil treatments with different EPA/DHA ratios
affect the histology of liver, kidney, adipose tissue and
aorta in a preliminary morphological study. This paper
uses an animal model of metabolic syndrome in com-
parison to healthy animals in order to provide informa-
tion about the best EPA: DHA ratio to prevent or to
improve MS symptoms.
Results
Aorta
Results in the aorta are shown in Table 1 and Figures 1
and 2.
The aortic walls in SHROB rats are less healthy than
those in Wistar rats: they are thicker and less dense, and
have less wrinkling. However, there is some improve-
ment in those rats consuming a EPA: DHA 1:1 treat-
ment. Both the density and wrinkling are greater in the
SHROB group supplemented with this proportion than
with the other treatments. Likewise, the thickness of the
wall is no different in this SHROB group than in the
same Wistar group.
No relationship was found between the anatomo-
pathological findings and oxidative stress. However,
aortic wall thickness was positively correlated with total
plasma cholesterol levels, and negatively correlatedTable 1 Aorta results
Thickness of wall (μm) Lumen area
mean ± SD mean ±
WISTAR EPA:DHA 1:1 101.60 ± 22.5 0.55 ± 0.
EPA:DHA 2:1 91.91 ± 9.91a 0.43 ± 0.
EPA:DHA 1:2 81.66 ± 5.47b 0.45 ± 0.
SHROB EPA:DHA 1:1 121.71 ± 18.04 0.56 ± 0.
EPA:DHA 2:1 109.39 ± 13.82a 0.49 ± 0.
EPA:DHA 1:2 122.82 ± 16.68b 0.64 ± 0.
The quantitative data are expressed by mean ± SD. Qualitative data are expressed a
(*) Statistical differences with respect to EPA:DHA 1:1 treatment p < 0.05.
The same letters in different strains mean significant statistical differences. p = 0.023with the HDL/LDL ratio (R2 = 0.613 and R2 = 0.658,
respectively).
Adipose tissue
Results in adipose tissue are shown in Table 2 and
Figure 3.
To sum up, SHROB rats present greater hypertrophy
and inflammation of the adipose tissue than Wistar rats.
The results for each treatment group show that the 1:1
ratio presented no mast cells in Wistar rats unlike other
groups. The 2:1 treatment decreased the number of mast
cells in the adipose tissue of SHROB rats with respect to
the other treatments. And, the 1:1 and 1:2 treatments
showed no macrophages in SHROB rats unlike the other
groups.
Liver
Results are shown in Figures 4 and 5. To sum up, in
liver, the presence of steatosis in the centrilobular zone
indicates initial harmful effects. The more widespread it
is, the more the injury has progressed and the more se-
vere it is. Therefore, periportal steatosis is worse than
centrilobular steatosis, and non-zonal inflammation is
the worst. In SHROB rats steatosis tended to be peripor-
tal, but no statistically significant differences were found
between treatment groups. As in the other tissues, in-
flammation was evaluated according to the presence of
white cells. SHROB rats also showed greater lobular in-
flammation than Wistar.
Kidney
Table 3 and Figure 6 shows the results of the different
variables studied in kidney. To sum up, kidney damage
was greater in SHROB than in Wistar rats. The 2:1 treat-
ment tends to worsen the kidney parameters in Wistar
rats, while the 1:1 treatment improves renal atrophy in
SHROB in comparison to the other tretments. The EPA:
DHA 1:1 treatment had the lowest presence of atrophy
followed by EPA:DHA 1:2. There were no differences in(mm2) Density of elastic tissue Wrinkling of elastic layers
SD Yes (%) Yes (%)
31 42.86 85.71
13 57.14 100c
10 100* 100d
19 100 28.57
13 33.33 0.00c
39 33.33 0.00d
s frequencies.
a, p < 0.001b, p = 0.002c, p = 0.002d.
Figure 1 Aortic wall thickness and wrinkling of elastic layers. Aortic wall thickness and wrinkling of elastic layers. Venhoeff & Van Gienson stain.
(400x). Images on the left: Wistar rats. Images on the right: SHROB rats. (A and B) EPA:DHA 1:1 treatment. (C and D) EPA:DHA 2:1 treatment.
(E and F) EPA:DHA 1:2 treatment. As we can see, images on the right, are thicker and less dense, and have less wrinkling, therefore are less functional.
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either between treatments or between strains.
Discussion
Although the relation between PUFA and cardiovascular
disease has been widely demonstrated [1,9,10], limited
information is available for histological changes.
Aorta
Data on various aortic layers are essential for under-
standing various diseases (such hypertension or diabetes)
that may remodel the tissue geometry and biomechan-
ical properties of the vascular wall differentially [11].
Only two previous studies have investigated the effect
of marine fatty acids on aorta histopathology. Park S.
and Park Y. results suggested that the hypolipidemic ac-
tion of fish oil had protective effects on aorta histopath-
ology in male Wistar rats [12]. And Engler, et al., who
show how DHA-fed spontaneously hypertensive rats
significantly reduced blood pressure and vascular wall
thicknesses in the coronary, thoracic, and abdominal
aorta compared with controls [13].In our study, despite the thickness of the aorta was
not affected by any of the treatments, the ratio EPA:
DHA 1:1 shown the highest value. And the highest value
of wrinkling too. This indicates a healthier condition. A
lower density of elastic layers and less wrinkling indi-
cates increased stiffness of the aorta which has been as-
sociated with greater vascular damage [11,14].
That’s the reason why the ratio EPA:DHA 1:1 is the
best at maintaining or improving the aorta’s structure,
and hence its function. We should emphasize that the
portion of the aorta was taken from the same zone,
therefore the results of the other variables can be attrib-
uted to diet or strain and not to the location of the tis-
sue sampling. All treatments had a similar fat and
energy content and, hence, the observed differences can
be attributed to the different EPA:DHA ratios.
Adipose tissue
According to the literature, omega 3 supplementation
prevents the inflammation of the adipose tissue in obese
and diabetic mice [9] and diminishes hypertrophy and
hyperplasia in that tissue [15]. Our results seem to be
Figure 2 Aorta results. At the top Histological cuts of abdominal aorta, Hematoxilin-eosin stain (400x) (A and B) EPA:DHA 1:1 in Wistar rat and
SHROB rat respectively. We can observe the wall of aorta with the muscular cells nucleus and intuit elastic bands. As we can see SHROB rats
presents a nuclei hypertrophy of aortic muscle cells than Wistar rats aortic muscle cells. When there was a nuclear hypertrophy of aortic muscle
cells, the size of the cells increased and, consequently, the density decreased and the elastic layers were less wrinkled. This indicates a decreased
health status. At the bottom four graphics (C) The different treatments did not affect the thickness of the aortic wall in either Wistar or SHROB
rats. The same letters in different strains mean significant statistical differences. p = 0.023a, p < 0.001b. (D) In aortic lumen area there were no
differences between Wistar and SHROB for any treatment or among treatments in each strain. This indicates that the portion of aorta was taken
from the same zone, which enables results to be compared. (E) Wrinkling was significantly higher in Wistar than SHROB for the EPA:DHA 2:1, EPA:
DHA 1:2 treatments (p = 0.002g and p = 0.002h respectively). The same letters mean significant statistical differences in different strains. (F) SHROB
rats showed less density than Wistar without significant differences. In SHROB rats group the best value was given by EPA:DHA 1:1 treatment.
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hypertrophy of tissue when the abdominal fat weight/
body weight ratio in SHROB rats (6.7-7.8%) was higher
than in Wistar rats (3.6-4.3%). There were significant
differences in all treatment groups. Treatments did not
affect this ratio in either Wistar or SHROB rats. This
may be because SHROB rats were too severely affectedTable 2 Adipose tissue results
Variable size Macrophages Mast
Yes (%) Yes (%) Yes
WISTAR EPA:DHA 1:1 28.57a 14.29 0
EPA:DHA 2:1 71.43 42.86 57
EPA:DHA 1:2 33 16.67 10
SHROB EPA:DHA 1:1 85.71a 0.00 85.7
EPA:DHA 2:1 57.14 14.30 42
EPA:DHA 1:2 42.86 0.00 10
Data are expressed as frequencies. The same letters in different strains mean signifi
(*): Differences with EPA:DHA 1:1. In mast cells % p < 0.001. (^): differences with EPAby the diseases or because the weekly recommended
dosage was too low.
The greater presence of differently-sized adipocytes
could be explained by the relation between PUFA, and
peroxisome-proliferator-activated receptor γ (PPARγ),
which plays a critical role in the regulation of adipocyte
differentiation. PUFA are potential ligands for this nuclearcells Inflammation
(%) No (%) Light (%) Moderate (%) Marked (%)
b 71.43 28.57 0.00 0.00
.14 85.71c 14.29 0.00 0.00
0* 66.67 33.33 0.00 0.00
1^b 28.57 71.43 0.00 0.00
.86 0.00c 100.00 0.00 0.00
0^ 42.86 57.14 0.00 0.00
cant statistical differences, p = 0.031a, p = 0.01b, p = 0.001c.
:DHA 2:1. In mast cells % p = 0.022, p = 0.018 respectively.
Figure 3 Adipose tissue results. At the top Histological cuts of adipose tissue, Hematoxilin-eosin stain (A) EPA:DHA 1:1 in SHROB rat (100x), we
can observe the variable size of adipocytes and intuit the presence of inflammatory cells. (B) EPA:DHA 1:2 in SHROB rat (300x) mast cells marked
up by black arrows. At the bottom four graphics in which: (W) refers to Wistar strain, (S) refers to SHROB strain. (A) EPA:DHA 1:1, (B) EPA:DHA 2:1,
(C) EPA:DHA 1:2. Equal letters, a, b, c, d, e means statistical differences among strains. (C) In both strain of rats there weren’t statistically significant
differences in the proportion of different adipocyte sizes among the treatment groups. Comparing the two strains, it was higher in SHROB rats
than in WISTAR rats for the EPA:DHA 1:1 diet (p = 0.031a). (D) As far as the presence of white cells, and therefore inflammation, is concerned; there
was a higher effect of PUFA n-3 in Wistar rats than in SHROB rats. In these strain only EPA:DHA 1:2 treatment doesn’t show a significant improvement
(p = 0.001c) (E) Mast cells % in Wistar rats showed differences with EPA:DHA 1:1 (p < 0.001*). And in SHROB rats (p = 0.022^, p = 0.018^ respectively)
Comparing the two strains, in the EPA:DHA 1:1 diet, SHROB showed a greater presence of mast cells than WISTAR (p = 0.001b). (F) The proportion of
macrophages in SHROB rats was lower than in Wistar rats but no significant differences were founded.
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have more adipocytes of different sizes [16]. The PPAR
family can also inhibit NF-кß factor transcription, which is
also related to inflammation [5]. This may explain why
PUFA prevents inflammation.
However, the effect of different types of PUFA on body
adiposity is still controversial. Omega-3 PUFA treat-
ments, as our results show, improve inflammation in this
tissue, especially in SHROB rats. Even being a very af-
fected model, after the EPA:DHA treatment SHROB rats
showed a slight inflammation or non- existent inflam-
mation in all cases.Liver
The effects of omega-3 PUFA on liver are the most contro-
versial, showing contradictory results [17,18]. In our study
Wistar rats showed better results in all the parameters de-
termined in liver, specifically EPA:DHA 1:1 treatment,which showed the best results, leading to a total absence of
any inflammatory process.
Various studies have shown that both the excess and
the total absence of omega 3 PUFA in experimental ani-
mals have given rise to hepatic steatosis [19,20]. This
could be explained by the nature of the PUFA n-3,
which is fat. It is therefore of the utmost importance to
establish the correct dosage range for these fatty acids.
In our study, in healthy rats - Wistar rats- , the best
treatment is EPA:DHA 1:1 implying a preventative role in
the liver. However in the group of rats affected -SHROB
rats- EPA:DHA 1:1 ratio also provides the less harmful lo-
cation of steatosis.
Kidney
Finally, epidemiological studies suggest that omega-3
PUFA slow down the progression of renal dysfunc-
tion in patients [21,22] and experimental models of
diabetes [23,24].
A B
DC
E F
Figure 4 Liver results. Graphics of liver results in which: (W) refers to WISTAR stain, (S) refers to SHROB stain. (A) EPA:DHA 1:1, (B) EPA:DHA 2:1,
(C) EPA:DHA 1:2. Equal letters, a, b, c, d, e means statistical differences among strains. (A) Liver samples of WISTAR rats no showed steatosis.
Consequently, between WISTAR and SHROB statistically significant differences were observed in all treatment groups (EPA:DHA 1:1 p = 0.001, EPA:
DHA 2:1 p = 0.001, EPA:DHA 1:2 p = 0.031). The graphics showns the grade of stetosi in SHROB rats, its location is shown in graphic (B) we can
see how in SHROB rats steatosis tended to be periportal, but no statistically significant differences were found between treatment groups.
(C) SHROB rats also showed greater lobular inflammation than Wistar. There were significant differences between strains in the EPA:DHA 2:1 and
EPA:DHA 1:2 treatments (p = 0.025* and p = 0.02^, respectively). (D) The presence of microgranulomas was higher in SHROB rats than in Wistar,
and the differences were significant in three tretament groups: EPA:DHA 2:1 (p = 0.005a). In SHROB fewer microgranulomas were present in the
EPA:DHA 1:1 and EPA:DHA 1:2 treatments, but there were no significant differences with other groups. (E) We found lipogranulomas in the
Wistar EPA:DHA 2:1 group and in all the groups of SHROB rats, with significant differences between strains for EPA:DHA 1:1 (p < 0.001), EPA:DHA
2:1 (p = 0.001), EPA:DHA 1:2 (p = 0.002). (F) Portal inflammation was present in both Wistar and SHROB rats but differences were only significant
between strains in the EPA: DHA 1:1 treatment (p < 0.001). No differences between treatments were found in the same strain.
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no renal dysfunction. A comparison of the treatments in
SHROB rats shows that EPA:DHA 1:1 did not cause
renal atrophy.
Considering the greater effect in Wistar rats than in
SHROB rats, treatments of marine fish-oil seem to be
more preventative than restorative in kidney tissue. As
in liver tissue.
All this suggests that within the protective role of
PUFA, the most appropriate ratio of its components is
EPA:DHA 1:1 ratio as has been already described in the
article of Lluis, et al. [4] carried on by our group. But
also improves histological parameters in Obese rats with
Metabolic Syndrome, as demonstrated in this work.Limitations
The SHROB strain, also known as the Koletsky rat, is
considered to be a good model for MS. It has mono-
genetic obesity superimposed on a hypertensive genetic
background. The obesity mutation is a recessive trait,
designated fak, which is a nonsense mutation of the lep-
tin receptor gene. This mutation renders the SHROB in-
capable of central and peripheral responses to leptin.
Animals can be identified as genetically obese at about
five weeks of age and they also develop premature vas-
cular disease, particularly of the abdominal arteries, al-
though, microscopically, the lesions that occur in these
vessels simulate those of human atherosclerosis [9]. The
SHROB rats also develop severe glomerulosclerosis and
Figure 5 Histological cuts of liver. Histological cuts of liver, Hematoxilin-eosin stain (A) EPA:DHA 2:1 treatment in SHROB rat (40x), shown
steatosis with periportal location (B) EPA:DHA 2:1 treatment in SHROB rat (400x), lobular inflammation marked up with a black arrow. The picture
also allows us to observe steatosi which is marked up, in part, with red arrows (C) EPA:DHA 2:1 in SHROB rat (600x), on the right some
macrophages surrounding a lipidic drop, forming a lipogrnaulome and on the left a lipogranulome also formed by macrophages. The picture
also allows us to observe steatosi at higher magnification (D) EPA:DHA 2:1 in Wistar rat (200x), portal inflammation, as we can see the
inflammatory cells are surrounding portal space.
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pharmacological studies with antihypertensive and antidia-
betic drugs but our results indicate that it is probably not
such a useful model for distinguishing subtle changes
caused by diets.
Conclusion
PUFA n-3 treatments – especially EPA:DHA 1:1 ratio–
improved the density and wrinkling of the elastic layers
in the abdominal aorta in SHROB rats and kidney atro-
phy as well. EPA:DHA 1:1 also improved the inflam-
mation parameters in the liver and the inflammation
parameters in adipose tissue in both groups of rats.
Therefore we can conclude that, Eicosapentaenoic acid/
Docosahexaenoic acid 1:1 ratio improves histologicalTable 3 Kidney results
Glomerulosclerosis Atr
Presence Absence Light
WISTAR EPA:DHA 1:1 0a 100 0
EPA:DHA 2:1 14.29 85.71 0
EPA:DHA 1:2 0 100 0
SHROB EPA:DHA 1:1 71.43a 100 0
EPA:DHA 2:1 57.14 71.43 28.57
EPA:DHA 1:2 42.86 85.71 0
The data are expressed as frequency. The same letters in different strains mean sign
Glomerulosclerosis: p = 0.005a.
Thyroidization: p = 0.003a, p = 0.032b, p = 0.005c.alterations in Obese Rats with Metabolic Syndrome which
is a progress in the study of morphological changes and
therefore functional changes of PUFA in the organism. It
is important to note that is a preliminary morphological
study, therefore most studies had to be done in this field.
Methods and procedures
Animals and supplementation
All the procedures agreed with the European Union
guidelines for the care and management of laboratory
animals and the pertinent permission was obtained from
the CSIC Subcommittee of Bioethical Issues.
Thirty-five female Wistar rats, as a control group,
and thirty-five spontaneously hypertensive obese rats
(SHROB), as a model of SM, were purchased fromophy Thyroidization
Middle Marked Absence Light Middle Marked
0 0 100a 0 0 0
14.29 0 71.43b 14.29 14.29 14.29
0 0 100c 0 0 0
0 0 0a 57.14 28.57 14.29
0 0 0b 57.14 14.29 28.57
14.29 0 0c 57.14 14.29 28.57
ificant statistical differences.
BA 
C
D
FE
Figure 6 Kidney results. At the top Histological cuts of kidney, Hematoxilin-eosin stain. (A) EPA:DHA 1:1 in SHROB rat (40x) thyroidization zones
are marked by black arrows. Thyroidization it’s a kind of atrophy which gives them the appearance of the follicles in the thyroid gland as we can
see in the picture (hence the name). (B) EPA:DHA 1:2 in SHROB rat (200x), inflammation in kidney can be observed by the presence of inflammatory
cells, also we can observe a normal glomerulus on the top and a glomerulus with glomerulosclerosis marked by a black arrow. At the bottom three
graphics in which: (W) refers to Wistar strain, (S) refers to SHROB strain. (A) EPA:DHA 1:1, (B) EPA:DHA 2:1, (C) EPA:DHA 1:2. Equal letters, a, b, c, d, e
means statistical differences among strains. (C) We found greater presence of glomerulosclerosis in SHROB rats than in Wistar rats, but significant
differences were found only in the EPA:DHA 1:1 treatment (p = 0.005a). (D) SHROB rats had greater thyroidization than Wistar rats in all treatment
groups p = 0.003a, p = 0.032b, p = 0.005c. (E) Atrophy was also higher in SHROB rats. EPA:1:1 doesn’t shown atrophy in either both treatments, but no
significant differences were founded. (F) Inflammation were better also in EPA:DHA 1:1 treatments in both strains, but without significant differences.
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old) were kept in an isolated room with a constantly
regulated temperature (22 ± 2°C), and controlled hu-
midity (50 ± 10%) in a 12 h. artificial light cycle. Both
groups of rats spent a prior period of adaptation that
lasted two weeks.
Rats of each strain were randomized into trhee groups
(7 rats each): EPA:DHA 1:1 group, EPA:DHA 2:1 group
and EPA:DHA 1:2 group. All groups were fed a standard
pelleted diet from Harlan Ibérica (Barcelona, Spain) and
had ad libitum access to water and food.
Oils with different EPA:DHA ratios were obtained by
mixing appropriate quantities of the commercial fish oils
AFAMPES 121 EPA (A.F.A.M.S.A., Vigo, Spain), Ener-
Zona Omega 3 RX (Milan, Italy) and Oligen liquid DHA
80% (IFIGEN-EQUIP 98, S.L., Barcelona).
The supplemented dose fish oils was in agreement
with the European Union’s recommendation on omega-3
PUFA [26]. All supplements had a similar fat and energy
content (55–66 mg of PUFA per 100 mg of total fatty
acid) as is specified in a previous study recently pub-
lished by our group [27]. However, they differed signifi-
cantly in the proportion of individual fatty acids. In fish
oil mixtures containing EPA:DHA ratios of 1:1, 2:1 and
1:2, EPA and DHA were the most abundant PUFA, mak-
ing up approximately 50 mg per 100 mg of fatty acidbetween them. Because PUFA are extremely susceptible
to oxidation and the potential toxic effects of lipid oxi-
dation by-products, the lipid oxidation level was checked
throughout the experiment (peroxide values < 5 meq.
oxygen per kg of oil).
Each group of rats (n = 7) had a weekly oral dose of
0.8 mL/Kg bodyweight of the oil supplements, for 13 weeks
administered by gavage.
Finally all rats were sacrificed at the age of 28 weeks.
The rats were anesthetized intraperitoneally with ketamine
and xylacine (80 mg/Kg and 10 mg/Kg body weight re-
spectively), and then killed by exsanguination. Tissue sam-
ples were collected from the abdominal aorta, abdominal
adipose tissue, liver, and kidney.
Tissue processing
The dissected tissues were divided into two parts: the
first one was quickly frozen in liquid nitrogen and stored
at -80°C, for various biochemical determinations, and
the second one was fixed in 10% formalin at pH 7.4, for
histological analysis. All tissues, except adipose tissue,
which was extracted from abdominal zone, were dis-
sected entirely.
The samples fixed in formalin were dehydrated in al-
cohol and embedded in paraffin. Then all tissues were
cut in typically 3 μm thick slices, using a steel Knife
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from the liver, kidney and adipose tissue were stained
with haematoxylin/eosin (Harris Hematoxylin. QCA).
Aorta sections were stained with hematoxylin/eosin, and
Verhoeff and van Gieson’s stain (Van Gieson kit 100
test 6 × 30 ml + 2 × 18 ml Casa Alvarez (WVG-1026).
Haematoxylin stains cell nuclei blue, while eosin stains
cytoplasm, connective tissue and other extracellular sub-
stances pink or red. Verhoeff and van Gieson's stain is a
mixture of picric and fuchsin acids which makes it pos-
sible to observe the elastic layers of the aorta wall byTable 4 Categorization of the parameters in the different tiss
Meaning Grade Meaning
Aorta Liver
Thickness of wall (μm) Steatosis
Lumen perimeter (mm) < 5%
Lumen area (mm2) 5-33%
Density of elastic bands 33-66%
Yes 1 > 66%
No 2 Localization of steato
Wrinkling of elastic layers Centrilobular
Yes 1 Periportal
Heterogeneous 2 No zonal
No 3
Nuclear hypertrophy Lobular inflammation
No 1 No
Heterogeneous 2 < 2 focus
Yes 3 2-4 focus
> 4 focus
Adipose tissue Portal inflammation
Differently sized adipocytes No
Yes 1 Yes
No 0 Fibrosis
Macrophages No
Presence 1 Perisinusoidal or p
Absence 0 Fibrosis bridges
Mast cells Cirrhosis
Presence 1 Microgranuloma
Absence 0 Absence
Inflammation Presence
No 0 Lipogranuloma
Light 1 Absence
Moderate 2 Presence
Marked 3 Macrophages
Absence
Presence
Categorization of the parameters in the different tissues based on the literature: Pa
Xu ZJ, et al.,2010 [29]; Dobrian, et al., 2003 [30].staining them dark blue. The sections of all tissues were
viewed under a light digital optical microscope (Leica
DMD 108) for histopathological changes.
Results of biochemical determinations such, as tissue
oxidative stress and plasma lipid profile are not shown
in this study, and were only used to establish correla-
tions with the parameters of pathological anatomy.
The tissue parameters were graded on the basis of the
histological findings (Table 4) [12,13,28-30].
The thickness of the aortic wall was examined at two
different points: maximum and minimum thickness. Theues
Grade Meaning Grade
Kidney
Glomerulosclerosis
0 Absence 0
1 Presence 1
2 Atrophy
3 Absence 0
sis Light 1
0 Middle 2
1 Marked 3
2 Thyroidization
Absence 0
Light 1
0 Middle 2
1 Marked 3
2 Fibrosis
3 Absence 0
Presence 1
0 Lipid depositions
1 Absence 0
Light 1
0 Moderate 2
eriportal 1 Inflammation
2 Absence 0
3 Light 1
Moderate 2
0 Marked 3
1
0
1
0
1
rk S and Park Y, 2009 [12]; Engler, et al., 2003 [13]; Muñoz, et al., 2009 [28];
Taltavull et al. Lipids in Health and Disease 2014, 13:31 Page 10 of 11
http://www.lipidworld.com/content/13/1/31mean of these two values was used. Semi quantitative
parameters were assessed by the consensus of three
observers.
Inflammation of adipose tissue, liver and kidney was
determined on the basis of the presence of inflammatory
cells in tissue [28,30].
Varying adipocyte sizes indicate hypertrophy in adi-
pose tissue. The more adipocytes there are of different
sizes, the greater the degree of tissue hypertrophy [28].
As well as inflammation, glomerulosclerosis, atrophy, fi-
brosis, lipid deposits and thyroidization were also evalu-
ated in kidney.
Thyroidization is the atrophy of some areas of the kid-
ney. The presence of thyroidization, then, does not indi-
cate a healthy status.
The results of the categorical variables were expressed
as the percentage of animals that presented the particu-
lar category in every variable (relative frequency).Statistical analysis
Statistical analysis was performed using SPSS IBM 19
software. The quantitative data are expressed by mean ±
SD and were compared among groups and treatments
using ANOVA with post-hoc tests for parametric data
and the U-Mann–Whitney for non-parametric data.
Qualitative data are expressed in frequencies, therefore,
percent of animals which present or not present the
variable. Relative frequencies were compared with con-
tingency tables using χ2 statistics. A p-value of <0.05 was
considered to be statistically significant. Results were
statistically correlated with oxidative stress and lipid pro-
file data.
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